Healthcare
Live Price
Offline$4.20
-2.55% today
1Y Change
-6.67%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Plus Therapeutics, Inc. (PSTV) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $4.20 and down 6.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -10.5%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -10.5%, EPS +100.0%, free cash flow -94.8% with operating margin -293.5% and ROIC -317.6%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PSTV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSTV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PSTV Max Drawdown
-86.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PSTV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$13.4M
+33.9% YoY
Free Cash Flow
-$10.4M
+24.1% YoY
Revenue Growth
-10.5%
EPS Growth
+100.0%
Gross Margin
91.5%
Net Margin
-429.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 6M | 5M | 224K | 0 |
| Gross Profit | 5M | 5M | -5M | -488K | -66K |
| Operating Income | -15M | -15M | -13M | -20M | -12M |
| EBITDA | -15M | -8M | -13M | -19M | -12M |
| Net Income | -22M | -13M | -13M | -20M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9M | 76K | 9M | 18M | 18M |
| Total Assets | 16M | 7M | 11M | 24M | 22M |
| Total Liabilities | 12M | 16M | 13M | 17M | 11M |
| Shareholder Equity | 4M | -9M | -1M | 6M | 11M |
| Total Debt | 821K | 3M | 4M | 6M | 7M |
| Net Debt | -8M | 3M | -4M | -12M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
+20.8% YoY
Capital Expenditures
144K
+81.0% YoY
Free Cash Flow
10M
+24.1% YoY
Key ratios
Gross Margin
91.5%
Operating Margin
-293.5%
Net Margin
-429.4%
ROE
774.8%
Debt / Equity
0.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.